Acacia Pharma says that it has successfully completed its first clinical trial, a Phase I study of APD 405 for the prevention and treatment of nausea and vomiting after surgery and chemotherapy.
The treatment is “an innovative intravenous formulation of a drug that is already widely available in tablet form” but a spokesman for the firm told PharmaTimes UK News that the identity of the drug is not being disclosed just yet for commercial reasons. The trial was conducted in 29 healthy male and female volunteers and demonstrated that APD 405 is safe and well-tolerated across a range of doses.
The results support further development of APD 405 and a Phase II study in adult patients undergoing surgery is planned to begin in the first quarter of 2009. Acacia chief executive Julian Gilbert said the Cambridge-based firm is delighted that APD 405 “has passed its first test so soon” and he remains confident that the drug, “with its exciting, multiple modes of action, will represent an important advance”.
Acacia added that the undisclosed active ingredient within APD 405 hits two proven, complementary, anti-emetic pathways, which are expected to be especially valuable in reducing nausea.
